La Corte Penal Internacional: últimas actuaciones y estado de los procedimientos en curso

La Corte Penal Internacional es el órgano jurisdiccional supranacional encargado de investigar y juzgar a los culpables de los crímenes más graves, los cuales se encuentran enumerados en el Estatuto de Roma. Desde su creación en 1998, la CPI ha sido una de las principales valedoras de la lucha contra la impunidad y el respeto a los derechos humanos en todo el mundo. En estos veinte años, numerosos casos han sido examinados por la Corte. En el presente trabajo se tratan los más representativos de las distintas fases del procedimiento: los casos de Georgia y Burundi para el examen preliminar, “Ruto y Sang” y “Kenyatta” en la fase de preparación del juicio oral, “Lubanga” y “Katanga” sobre la sentencia condenatoria, “Gbagbo y Blé Goudé” para la sentencia absolutoria, y el caso “Bemba”, sobre la fase de apelación. Finalmente, se analizan los problemas que se derivan del proceso, así como los nuevos desafíos a los que se enfrenta la Corte Penal Internacional.Departamento de Derecho Constitucional, Procesal y Eclesiástico del EstadoGrado en Derech

Physicochemical composition and antioxidant activity of several pomegranate (Punica granatum L.) cultivars grown in Spain

[EN] Nine pomegranate cultivars grown in Spain were selected, and their physicochemical (total soluble solids, pH, titratable acidity, maturity index, monomeric anthocyanin pigment, flavonoids, hydrolyzable tannins, and vitamin C) and antioxidant properties and polyphenolic composition of the juices were compared. A total of 53 polyphenols were identified, showing cultivars different profiles. Of all nine cultivars, Katirbasi had the highest contents of flavonoids, hydrolyzable tannins and vitamin C, as well as gallic acid and ellagic acid contents, explaining its high total reducing capacity. Principal component analysis allowed Katirbasi to be differentiated clearly from the others. Other cultivars presented also interesting characteristics such as high monomeric anthocyanin pigment content (CG8 cultivar) and interesting antioxidant activity (Wonderful 2 and CG8 cultivars). CG8 was the cultivar with the highest value of cyanidin-3,5-di-O-glucoside. Thus, this study will assist pomegranate producers in choosing the most suitable cultivar according to its ultimate use.Authors are grateful to POCTEP-Programa de Cooperacao Transfronteirica Espanha-Portugal for financial support through the Project "RED/AGROTEC - Experimentation network and transfer for development of agricultural and agro industrial sectors between Spain and Portugal" and CIMO through the Project PEst-OE/AGR/UI0690/2014 and the Foundation for Science and Technology (FCT, Portugal) and FEDER under Programme PT2020 for financial support to CIMO (UID/AGR/00690/2013).Fernandes, L.; Pereira, JA.; López- Cortés, I.; Salazar Hernández, DM.; González-Álvarez, J.; Ramalhosa, E. (2017). Physicochemical composition and antioxidant activity of several pomegranate (Punica granatum L.) cultivars grown in Spain. European Food Research and Technology. 243(10):1799-1814. https://doi.org/10.1007/s00217-017-2884-4S1799181424310Andreu-Sevilla AJ, Signes-Pastor AJ, Carbonell-Barrachina AA (2009) La granada: producción, composición y propiedades beneficiosas para la salud. In Informe de la Universidad Miguel Hernández, Elche, Elchedigital.es, SpainHolland D, Hatib K, Bar-Ya’akov I (2009) Pomegranate: botany, horticulture, breeding. Hortic Rev 35:127–191Mena P, García-Viguera C, Navarro-Rico J, Moreno DA, Bartual J, Saura D, Martí N (2011) Phytochemical characterisation for industrial use of pomegranate (Punica granatum L.) cultivars grown in Spain. J Sci Food Agric 91:1893–1906Akpinar-Bayizit A, Ozcan T, Yilmaz-Ersan L (2012) The therapeutic potential of pomegranate and its products for prevention of cancer. In: Georgakilas AG (ed) Cancer prevention—from mechanisms to translational benefits. InTech, CroatiaDepartment of Agriculture and Food, Western Australia, Growing pomegranates in Western Australia. http://www.agric.wa.gov.au . Accessed 29th Oct 2013Gil MI, Tomás-Barberán FA, Hess-Pierce B, Holcroft DM, Kader AA (2000) Antioxidant activity of pomegranate juice and its relationship with phenolic composition and processing‎. J Agric Food Chem 48:4581–4589Hernández F, Melgarejo P, Tomás-Barberán FA, Artés F (1999) Evolution of juice anthocyanins during ripening of new selected pomegranate (Punica granatum) clones. Eur Food Res Technol 210:39–42Jurenka J (2008) Therapeutic applications of pomegranate (Punica granatum L.): a review. Altern Med Rev 13:128–144Legua P, Melgarejo P, Martínez M, Hernández F (2009) Evolution of anthocyanin content of four pomegranate cultivars (Punica granatum L.) during fruit development. In: Melgarejo P, Martínez-Nicolás JJ, Martínez-Tomé J (eds) Production, processing and marketing of pomegranate in the Mediterranean region: Advances in research and technology, Options Méditerranéennes: Série A. Séminaires Méditerranéens, n. 42: CIHEAM, MadridMelgarejo P, Salazar DM, Artés F (2000) Organic acids and sugars composition of harvested pomegranate fruits. Eur Food Res Technol 211:185–190Nuncio-Jáuregui N, Nowicka P, Munera-Picazo S, Hernández F, Carbonell-Barrachina AA, Wojdyło A (2015) Identification and quantification of major derivatives of ellagic acid and antioxidant properties of thinning and ripe Spanish pomegranates. J Funct Foods 12:354–364Viuda-Martos M, Ruiz-Navajas Y, Fernández-López J, Sendra E, Sayas-Barberá E, Pérez-Álvarez JA (2011) Antioxidant properties of pomegranate (Punica granatum L.) bagasses obtained as co-product in the juice extraction. Food Res Int 44:1217–1223Aviram M, Dornfeld L, Rosenblat M, Volkova N, Kaplan M, Coleman R, Hayek T, Presser D, Fuhrman B (2000) Pomegranate juice consumption reduces oxidative stress, atherogenic modifications to LDL, and platelet aggregation: studies in humans and in atherosclerotic apolipoprotein E–deficient mice. Am J Clin Nutr 71:1062–1076Basu A, Penugonda K (2009) Pomegranate juice: a heart-healthy fruit juice. ‎Nutr Rev 67:49–56Albrecht M, Jiang W, Kumi-Diaka J, Lansky EP, Gommersall LM, Patel A, Mansel RE, Neeman I, Geldof AA, Campbell MJ (2004) Pomegranate extracts potently suppress proliferation, xenograft growth, and invasion of human prostate cancer cells. J Med Food 7:274–283Lansky E, Shubert S, Neeman I (2000) Pharmacological and therapeutic properties of pomegranate. In: Melgarejo P, Martínez-Nicolás JJ, Martínez-Tomé J (eds) Production, processing and marketing of pomegranate in the Mediterranean region: Advances in research and technology. Options Méditerranéennes: Série A. Séminaires Méditerranéens; n. 42, CIHEAM, MadridLansky EP, Newman RA (2007) Punica granatum (pomegranate) and its potential for prevention and treatment of inflammation and cancer. J Ethnopharmacol 109:177–206Rahimi HR, Arastoo M, Ostad SN (2012) A comprehensive review of Punica granatum (pomegranate) properties in toxicological, pharmacological, cellular and molecular biology researches. Iran J Pharm Res 11:385–400Tomás-Barberán FA (2010) Granada y salud: aspectos farmacológicos y terapéuticos de la granada. In: Moreno PM, García FH, Murcia PL (eds) Jornadas Nacionales sobre el granado: producción, economía, industrialización, alimentación y salud. SPE3, ValenciaWu D, Ma X, Tian W (2013) Pomegranate husk extract, punicalagin and ellagic acid inhibit fatty acid synthase and adipogenesis of 3T3-L1 adipocyte. J Funct Foods 5:633–641Maestre J, Melgarejo P, Tomás-Barberán FA, García-Viguera C (2000) New food products derived from pomegranate. In: Melgarejo P, Martínez-Nicolás JJ, Martínez-Tomé J (eds) Production, processing and marketing of pomegranate in the Mediterranean region: advances in research and technology. Options Méditerranéennes: Série A. Séminaires Méditerranéens; n. 42, CIHEAM, MadridOrdoudi SA, Mantzouridou F, Daftsiou E, Malo C, Hatzidimitriou E, Nenadis N, Tsimidou MZ (2014) Pomegranate juice functional constituents after alcoholic and acetic acid fermentation. J Funct Foods 8:161–168Park JE, Kim JY, Kim J, Kim YJ, Kim MJ, Kwon SW, Kwon O (2014) Pomegranate vinegar beverage reduces visceral fat accumulation in association with AMPK activation in overweight women: a double-blind, randomized, and placebo-controlled trial. J Funct Foods 8:274–281Magerramov MA, Abdulagatov AI, Azizov ND, Abdulagatov IM (2007) Effect of temperature, concentration, and pressure on the viscosity of pomegranate and pear juice concentrates. J Food Process Eng 80:476–489Madrigal-Carballo S, Rodriguez G, Krueger CG, Dreher M, Reed JD (2009) Pomegranate (Punica granatum) supplements: authenticity, antioxidant and polyphenol composition. J Funct Foods 1:324–329Tehranifar A, Zarei M, Nemati Z, Esfandiyari B, Vazifeshenas MR (2010) Investigation of physico-chemical properties and antioxidant activity of twenty Iranian pomegranate (Punica granatum L.) cultivars. Sci Hort 126:180–185Zarei M, Azizi M, Bashiri-Sadr Z (2010) Studies on physico-chemical properties and bioactive compounds of six pomegranate cultivars grown in Iran. J Food Technol 8:112–117Gözlekçi Ş, Saraçoğlu O, Onursal E, Özgen M (2011) Total phenolic distribution of juice, peel, and seed extracts of four pomegranate cultivars. ‎Pharmacogn Mag 7:161–164Ozgen M, Durgaç C, Serçe S, Kaya C (2008) Chemical and antioxidant properties of pomegranate cultivars grown in the Mediterranean region of Turkey. Food Chem 111:703–706Gadže J, Voća S, Čmelik Z, Mustać I, Ercisli S, Radunić M (2012) Physico-chemical characteristics of main pomegranate (Punica granatum L.) cultivars grown in Dalmatia region of Croatia. J Appl Bot Food Qual 85:202–206Radunić M, Špika MJ, Ban SG, Gadže J, Lean DM (2012) Chemical composition of pomegranate (Punica granatum L.) cultivars grown in Croatia. In: Melgarejo P, Valero D (eds) II International Symposium on the Pomegranate, Options Méditerranéennes—Series A: Mediterranean Seminars, CIHEAM, ValenciaLegua P, Melgarejo P, Abdelmajid H, Martínez JJ, Martínez R, Ilham H, Hafida H, Hernández F (2012) Total phenols and antioxidant capacity in 10 Moroccan pomegranate varieties‎. J Food Sci 71:115–120Ferrara G, Giancaspro A, Mazzeo A, Giove SL, Matarrese MAS, Pacucci C, Punzi R, Trani A, Gambacorta G, Blanco A, Gadaleta A (2014) Characterization of pomegranate (Punica granatum L.) genotypes collected in Puglia region Southeastern Italy. Sci Hort 178:70–78Hernández F, Legua P, Martínez M, Melgarejo P (2000) Evolution of sugars and organic acid content in three pomegranate cultivars (Punica granatum L.). In: Melgarejo P, Martínez-Nicolás JJ, Martínez-Tomé J (eds) Production, processing and marketing of pomegranate in the Mediterranean region: Advances in research and technology, Options Méditerranéennes: Série A. Séminaires Méditerranéens; n. 42, CIHEAM, MadridLegua P, Melgarejo P, Martínez JJ, Martínez R, Hernández F (2012) Evaluation of Spanish pomegranate juices: organic acids, sugars, and anthocyanins. Int J Food Prop 15:481–494Martínez JJ, Melgarejo P, Hernández F, Salazar DM, Martínez R (2006) Seed characterisation of five new pomegranate (Punica granatum L.) varieties. Sci Hort 110:241–246Vegara S, Martí N, Lorente J, Coll L, Streitenberger S, Valero M, Saura D (2014) Chemical guide parameters for Punica granatum cv. ‘Mollar’ fruit juices processed at industrial scale. Food Chem 147:203–208Council Regulation (EEC) No 2092/91 of 24 June 1991 on organic production of agricultural products and indications referring thereto on agricultural products and foodstuffsMeier U (2001) BBCH monograph—growth stages of mono and dicotyledonous plants. Federal Biological Research Centre for Agriculture and Forestry, BonnMelgarejo P, Salazar D (2003) Treaty of fruit production for arid and semi-arid areas: carob, pomegranate and jujube, vol II. Mundi-Prensa Libras S.A, Madrid (in Spanish)Codex Alimentarius Commission (2012) Report of the 17th session of the Codex Committee on fresh fruits and vegetables. Codex Alimentarius Commission, Mexico CityDafny-Yalin M, Glazer I, Bar-Ilan I, Kerem Z, Holland D, Amir R (2010) Color, sugars and organic acids composition in aril juices and peel homogenates prepared from different pomegranate accessions. J Agric Food Chem 58:4342–4352Shwartz E, Glazer I, Bar-Ya’akov I, Matityahu I, Bar-Ilan I, Holland D, Amir R (2009) Changes in chemical constituents during the maturation and ripening of two commercially important pomegranate accessions. Food Chem 115:965–973Melgarejo P, Calín-Sánchez A, Vázquez-Aráujo L, Hernández F, Martínez JJ, Legua P, Carbonell-Barrachina AA (2011) Volatile composition of pomegranates from 9 Spanish cultivars using headspace solid phase microextraction. J Food Sci 76:114–120Bchir B, Besbes S, Karoui R, Attia H, Paquot M, Blecker C (2012) Effect of air-drying conditions on physico-chemical properties of osmotically pre-treated pomegranate seeds. Food Bioprocess Technol 5:1840–1852Rajasekar D, Akoh CC, Martino KG, MacLean DD (2012) Physico-chemical characteristics of juice extracted by blender and mechanical press from pomegranate cultivars grown in Georgia. Food Chem 133:1383–1393Elfalleh W, Hannachi H, Tlili N, Yahia Y, Nasri N, Ferchichi A (2012) Total phenolic contents and antioxidant activities of pomegranate peel, seed, leaf and flower. J Med Plants Res 6:4724–4730Falcão AP, Chaves ES, Kuskoski EM, Fett R, Falcão LD, Bordignon-Luiz MT (2007) Total polyphenol index, total anthocyanins and antioxidant activity of a model system of grape jelly. Ciênc Tecnol Aliment 27:637–642Delgado T, Malheiro R, Pereira JA, Ramalhosa E (2010) Hazelnut (Corylus avellana L.) kernels as a source of antioxidants and their potential in relation to other nuts. Ind Crops Prod 32:621–626Mena P, Calani L, Dall’Asta C, Galaverna G, García-Viguera C, Bruni R, Crozier A, Del Rio D (2012) Rapid and comprehensive evaluation of (Poly)phenolic compounds in pomegranate (Punica granatum L.) juice by UHPLC-MS. Molecules 17:14821–14840Calani L, Beghè D, Mena P, Del Rio D, Bruni R, Fabbri A, Dall’Asta C, Galaverna G (2013) Ultra-HPLC–MSn (Poly)phenolic profiling and chemometric analysis of juices from ancient Punica granatum L. Cultivars: a nontargeted approach‎. J Agric Food Chem 61:5600–5609Raduníc M, Špika MJ, Ban SG, Gadze J, Diáz-Pérez JC, MacLean D (2015) Physical and chemical properties of pomegranate fruit accessions from Croatia. Food Chem 177:53–60Ferrara G, Cavoski I, Pacifico A, Tedone L, Mondelli D (2011) Morpho-pomological and chemical characterization of pomegranate (Punica granatum L.) genotypes in Apulia region, Southeastern Italy. Sci Hort 130:599–606Melgarejo P, Sánchez M, Hernández F, Martínez JJ, Amorós A (2012) Parameters for determining the hardness and pleasantness of pomegranates (Punica granatum L.). In: Melgarejo P, Martínez-Nicolás JJ, Martínez-Tomé J (eds) Production, processing and marketing of pomegranate in the Mediterranean region: advances in research and technology, Options Méditerranéennes: Série A. Séminaires Méditerranéens; n. 42: CIHEAM, MadridFDA acidified and low-acid canned foods—approximate pH of foods and food products. U.S. Food and Drug Administration www.cfsan.fda.gov . Accessed 29th Oct 2013Melgarejo-Sánchez P, Martínez JJ, Legua P, Martínez R, Hernández F, Melgarejo P (2015) Quality, antioxidant activity and total phenols of six Spanish pomegranates clones. Sci Hort 182:65–72Opara LU, Al-Ani MR, Al-Shuaibi YS (2009) Physico-chemical properties, vitamin C content, and antimicrobial properties of pomegranate fruit (Punica granatum L.). Food Bioprocess Tech 2:315–321Mars M, Melgarejo P, Amorós A, Martínez R (1997) Pomegranate descriptors. In: Instituto Agronómico Mediterráneo de Zaragoza (IAMZ) (ed) Collaborative Working Group on Underutilized Fruit Crops in the Mediterranean Region, CIHEAM, ZaragozaDe Palma L, Novello V (1995) II melograno: attualitá di una coltura antica. Rivista di Frutticoltura 11:45–49Pavez IAC (2011) Caracterización física, química y sensorial de frutos de granado cv. Wonderful provenientes de tres regiones de Chile, Final course work. Universidad de Chile, Facultad de Ciencias Agronómicas, Santiago do ChileCristofori V, Caruso D, Latini G, Dell’Agli M, Cammilli C, Rugini E, Bignami C, Muleo R (2011) Fruit quality of Italian pomegranate (Punica granatum L.) autochthonous varieties. Eur Food Res Technol 232:397–403Martínez JJ, Hernández F, Abdelmajid H, Legua P, Martínez R, Amine AE, Melgarejo P (2012) Physico-chemical characterization of six pomegranate cultivars from Morocco: processing and fresh market aptitudes. Sci Hort 140:100–106Chace EM, Church CG, Poore HD (1930) The Wonderful variety of pomegranate: composition, commercial maturity, and by-products. In: United States Department of Agriculture (ed), Circular No 98, U.S. Government Printing Office, WashingtonSepúlveda E, Sáenz C, Peña A, Robert P, Bartolomé B, Gómez-Cordovés C (2010) Influence of the genotype on the anthocyanin composition, antioxidant capacity and color of Chilean pomegranate (Punica granatum L.) juices. Chil. J Agric Res 70:50–57Elfalleh W, Yahia Y, Ferchichi A (2012) Main pomegranate phytochemicals and their contribution to the antioxidant potencies of pomegranate juice. In: Melgarejo P, Valero D (eds) II International Symposium on the pomegranate, Options Méditerranéennes—Series A: Mediterranean Seminars. CIHEAM, MadridHirth M, Leiter A, Beck SM, Schuchmann HP (2014) Effect of extrusion cooking process parameters on the retention of bilberry anthocyanins in starch based food. J Food Eng 125:139–146Orak HH, Yagar H, Isbilir SS (2012) Comparison of antioxidant activities of juice, peel, and seed of pomegranate (Punica granatum L.) and inter-relationships with total phenolic, tannin, anthocyanin, and flavonoid contents. Food Sci Biotechnol 21:373–387Paul R, Ghosh U (2012) Effect of thermal treatment on ascorbic acid content of pomegranate juice. IJBT 11:309–313Tezcan F, Gültekin-Özgüven M, Diken T, Özçelik B, Erim FB (2009) Antioxidant activity and total phenolic, organic acid and sugar content in commercial pomegranate juices. Food Chem 115:873–877Li X, Wasila H, Liu L, Yuan T, Gao Z, Zhao B, Ahmad I (2015) Physicochemical characteristics, polyphenol compositions and antioxidant potential of pomegranate juices from 10 Chinese cultivars and the environmental factors analysis. Food Chem 175:575–584Bonarska-Kujawa D, Pruchnik H, Kleszczyńska H (2012) Interaction of selected anthocyanins with erythrocytes and liposome membranes. Cell Mol Biol Lett 17:289–30

Efficacy and Safety of Oral Fosfomycin for Asymptomatic Bacteriuria in Kidney Transplant Recipients: Results from a Spanish Multicenter Cohort

Current guidelines recommend against systematic screening for or treating asymptomatic bacteriuria (AB) among kidney transplant (KT) recipients, although the evidence regarding episodes occurring early after transplantation or in the presence of anatomical abnormalities is inconclusive. Oral fosfomycin may constitute a good option for the treatment of posttransplant AB, particularly due to the emergence of multidrug-resistant (MDR) uropathogens. Available clinical evidence supporting its use in this specific setting, however, remains scarce. We performed a retrospective study in 14 Spanish institutions from January 2005 to December 2017. Overall, 137 episodes of AB diagnosed in 133 KT recipients treated with oral fosfomycin (calcium and trometamol salts) with a test-of-cure urine culture within the first 30 days were included. Median time from transplantation to diagnosis was 3.1 months (interquartile range [IQR], 1.1 to 10.5). Most episodes (96.4% [132/137]) were caused by Gram-negative bacteria (GNB), and 56.9% (78/137) were categorized as MDR (extended?spectrum ??lactamase?producing Enterobacterales [20.4%] and carbapenem?resistant GNB [2.9%]). Rate of microbiological failure at month 1 was 40.1% (95% confidence interval [CI], 31.9% to 48.9%) for the whole cohort and 42.3% (95% CI, 31.2% to 54.0%) for episodes due to MDR pathogens. Previous urinary tract infection (odds ratio [OR], 2.42; 95% CI, 1.11 to 5.29; P value = 0.027) and use of fosfomycin as salvage therapy (OR, 8.31; 95% CI, 1.67 to 41.35; P value = 0.010) were predictors of microbiological failure. No severe treatment-related adverse events were detected. Oral fosfomycin appears to be a suitable and safe alternative for the treatment (if indicated) of AB after KT, including those episodes due to MDR uropathogens.ACKNOWLEDGMENTS This study was supported by Plan Nacional de I+D+i 2013‐2016 and Instituto de Salud Carlos III (ISCIII), Subdirección General de Redes y Centros de Investigación Cooperativa, Ministry of Science and Innovation, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016), and Spanish Network for Research in Renal Diseases (REDInREN RD16/0009) and cofinanced by the European Development Regional Fund entitled A way to achieve Europe. M.F.-R. holds a research contract (Miguel Servet, CP18/00073), from the Spanish Ministry of Science and Innovation, ISCIII. Funding sources were not involved in the study design and conduction, data analysis, or manuscript preparation

Impact of HLA Mismatching on Early Subclinical Inflammation in Low-Immunological-Risk Kidney Transplant Recipients

The impact of human leukocyte antigen (HLA)-mismatching on the early appearance of subclinical inflammation (SCI) in low-immunological-risk kidney transplant (KT) recipients is undetermined. We aimed to assess whether HLA-mismatching (A-B-C-DR-DQ) is a risk factor for early SCI. As part of a clinical trial (Clinicaltrials.gov, number NCT02284464), a total of 105 low-immunological-risk KT patients underwent a protocol biopsy on the third month post-KT. As a result, 54 presented SCI, showing a greater number of total HLA-mismatches (p = 0.008) and worse allograft function compared with the no inflammation group (48.5 ± 13.6 vs. 60 ± 23.4 mL/min; p = 0.003). Multiple logistic regression showed that the only risk factor associated with SCI was the total HLA-mismatch score (OR 1.32, 95%CI 1.06-1.64, p = 0.013) or class II HLA mismatching (OR 1.51; 95%CI 1.04-2.19, p = 0.032) after adjusting for confounder variables (recipient age, delayed graft function, transfusion prior KT, and tacrolimus levels). The ROC curve illustrated that the HLA mismatching of six antigens was the optimal value in terms of sensitivity and specificity for predicting the SCI. Finally, a significantly higher proportion of SCI was seen in patients with >6 vs. ≤6 HLA-mismatches (62.3 vs. 37.7%; p = 0.008). HLA compatibility is an independent risk factor associated with early SCI. Thus, transplant physicians should perhaps be more aware of HLA mismatching to reduce these early harmful lesions

Clinical Relevance of Corticosteroid Withdrawal on Graft Histological Lesions in Low-Immunological-Risk Kidney Transplant Patients

The impact of corticosteroid withdrawal on medium-term graft histological changes in kidney transplant (KT) recipients under standard immunosuppression is uncertain. As part of an open-label, multicenter, prospective, phase IV, 24-month clinical trial (ClinicalTrials.gov, NCT02284464) in low-immunological-risk KT recipients, 105 patients were randomized, after a protocol-biopsy at 3 months, to corticosteroid continuation (CSC, n = 52) or corticosteroid withdrawal (CSW, n = 53). Both groups received tacrolimus and MMF and had another protocol-biopsy at 24 months. The acute rejection rate, including subclinical inflammation (SCI), was comparable between groups (21.2 vs. 24.5%). No patients developed dnDSA. Inflammatory and chronicity scores increased from 3 to 24 months in patients with, at baseline, no inflammation (NI) or SCI, regardless of treatment. CSW patients with SCI at 3 months had a significantly increased chronicity score at 24 months. HbA1c levels were lower in CSW patients (6.4 +/- 1.2 vs. 5.7 +/- 0.6%; p = 0.013) at 24 months, as was systolic blood pressure (134.2 +/- 14.9 vs. 125.7 +/- 15.3 mmHg; p = 0.016). Allograft function was comparable between groups and no patients died or lost their graft. An increase in chronicity scores at 2-years post-transplantation was observed in low-immunological-risk KT recipients with initial NI or SCI, but CSW may accelerate chronicity changes, especially in patients with early SCI. This strategy did, however, improve the cardiovascular profiles of patients

Oral fosfomycin for the treatment of lower urinary tract infections among kidney transplant recipients—Results of a Spanish multicenter cohort

Preliminary results of this study were presented at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), held in Amsterdam, The Netherlands, from 13 to 16 April, 2019 (oral communication O‐0699).Oral fosfomycin may constitute an alternative for the treatment of lower urinary tract infections (UTIs) in kidney transplant recipients (KTRs), particularly in view of recent safety concerns with fluroquinolones. Specific data on the efficacy and safety of fosfomycin in KTR are scarce. We performed a retrospective study in 14 Spanish hospitals including KTRs treated with oral fosfomycin (calcium and trometamol salts) for posttransplant cystitis between January 2005 and December 2017. A total of 133 KTRs developed 143 episodes of cystitis. Most episodes (131 [91.6%]) were produced by gram‐negative bacilli (GNB), and 78 (54.5%) were categorized as multidrug resistant (including extended‐spectrum β‐lactamase‐producing Enterobacteriaceae [14%] or carbapenem‐resistant GNB [3.5%]). A median daily dose of 1.5 g of fosfomycin (interquartile range [IQR]: 1.5‐2) was administered for a median of 7 days (IQR: 3‐10). Clinical cure (remission of UTI‐attributable symptoms at the end of therapy) was achieved in 83.9% (120/143) episodes. Among those episodes with follow‐up urine culture, microbiological cure at month 1 was achieved in 70.2% (59/84) episodes. Percutaneous nephrostomy was associated with a lower probability of clinical cure (adjusted odds ratio: 10.50; 95% confidence interval: 0.98‐112.29; P = 0.052). In conclusion, fosfomycin is an effective orally available alternative for treating cystitis among KTRs.This study was supported by Plan Nacional de I+D+i 2013‐2016 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Ciencia, Innovación y Universidades, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016)—cofinanced by the European Development Regional Fund “A way to achieve Europe”; the Group for Study of Infection in Transplantation and the Immunocompromised Host (GESITRA‐IC) of the Spanish Society of Clinical Microbiology and Infectious Diseases (SEIMC); and the Spanish Network for Research in Renal Diseases (REDInREN RD16/0009). MFR holds a research contract “Miguel Servet” (CP 18/00073) from the Spanish Ministry of Science, Innovation and Universities, Instituto de Salud Carlos III

Impact of interstitial lung disease on the survival of systemic sclerosis with pulmonary arterial hypertension

To assess severity markers and outcomes of patients with systemic sclerosis (SSc) with or without pulmonary arterial hypertension (PAH-SSc/non-PAH-SSc), and the impact of interstitial lung disease (ILD) on PAH-SSc. Non-PAH-SSc patients from the Spanish SSc registry and PAH-SSc patients from the Spanish PAH registry were included. A total of 364 PAH-SSc and 1589 non-PAH-SSc patients were included. PAH-SSc patients had worse NYHA-functional class (NYHA-FC), worse forced vital capacity (FVC) (81.2 +/- 20.6% vs 93.6 +/- 20.6%, P < 0.001), worse tricuspid annular plane systolic excursion (TAPSE) (17.4 +/- 5.2 mm vs 19.9 +/- 6.7 mm, P < 0.001), higher incidence of pericardial effusion (30% vs 5.2%, P < 0.001) and similar prevalence of ILD (41.8% vs. 44.9%). In individuals with PAH-SSc, ILD was associated with worse hemodynamics and pulmonary function tests (PFT). Up-front combination therapy was used in 59.8% and 61.7% of patients with and without ILD, respectively. Five-year transplant-free survival rate was 41.1% in PAH-SSc patients and 93.9% in non-PAH-SSc patients (P < 0.001). Global survival of PAH-SSc patients was not affected by ILD regardless its severity. The multivariate survival analysis in PAH-SSc patients confirmed age at diagnosis, worse NYHA-FC, increased PVR, reduced DLCO, and lower management with up-front combination therapy as major risk factors. In conclusion, in PAH-SSc cohort risk of death was greatly increased by clinical, PFT, and hemodynamic factors, whereas it was decreased by up-front combination therapy. Concomitant ILD worsened hemodynamics and PFT in PAH-SSc but not survival regardless of FVC impairment

Randomized Controlled Trial Assessing the Impact of Tacrolimus Versus Cyclosporine on the Incidence of Posttransplant Diabetes Mellitus

Despite the high incidence of posttransplant diabetes mellitus (PTDM) among high-risk recipients, no studies have investigated its prevention by immunosuppression optimization. We conducted an open-label, multicenter, randomized trial testing whether a tacrolimus-based immunosuppression and rapid steroid withdrawal (SW) within 1 week (Tac-SW) or cyclosporine A (CsA) with steroid minimization (SM) (CsA-SM), decreased the incidence of PTDM compared with tacrolimus with SM (Tac-SM). All arms received basiliximab and mycophenolate mofetil. High risk was defined by age >60 or >45 years plus metabolic criteria based on body mass index, triglycerides, and high-density lipoprotein-cholesterol levels. The primary endpoint was the incidence of PTDM after 12 months. The study comprised 128 de novo renal transplant recipients without pretransplant diabetes (Tac-SW: 44, Tac-SM: 42, CsA-SM: 42). The 1-year incidence of PTDM in each arm was 37.8% for Tac-SW, 25.7% for Tac-SM, and 9.7% for CsA-SM (relative risk [RR] Tac-SW vs. CsA-SM 3.9 [1.2-12.4; P = 0.01]; RR Tac-SM vs. CsA-SM 2.7 [0.8-8.9; P = 0.1]). Antidiabetic therapy was required less commonly in the CsA-SM arm (P = 0.06); however, acute rejection rate was higher in CsA-SM arm (Tac-SW 11.4%, Tac-SM 4.8%, and CsA-SM 21.4% of patients; cumulative incidence P = 0.04). Graft and patient survival, and graft function were similar among arms. In high-risk patients, tacrolimus-based immunosuppression with SM provides the best balance between PTDM and acute rejection incidence

Impact of interstitial lung disease on the survival of systemic sclerosis with pulmonary arterial hypertension

To assess severity markers and outcomes of patients with systemic sclerosis (SSc) with or without pulmonary arterial hypertension (PAH-SSc/non-PAH-SSc), and the impact of interstitial lung disease (ILD) on PAH-SSc. Non-PAH-SSc patients from the Spanish SSc registry and PAH-SSc patients from the Spanish PAH registry were included. A total of 364 PAH-SSc and 1589 non-PAH-SSc patients were included. PAH-SSc patients had worse NYHA-functional class (NYHA-FC), worse forced vital capacity (FVC) (81.2 ± 20.6% vs 93.6 ± 20.6%, P &lt; 0.001), worse tricuspid annular plane systolic excursion (TAPSE) (17.4 ± 5.2 mm vs 19.9 ± 6.7 mm, P &lt; 0.001), higher incidence of pericardial effusion (30% vs 5.2%, P &lt; 0.001) and similar prevalence of ILD (41.8% vs. 44.9%). In individuals with PAH-SSc, ILD was associated with worse hemodynamics and pulmonary function tests (PFT). Up-front combination therapy was used in 59.8% and 61.7% of patients with and without ILD, respectively. Five-year transplant-free survival rate was 41.1% in PAH-SSc patients and 93.9% in non-PAH-SSc patients (P &lt; 0.001). Global survival of PAH-SSc patients was not affected by ILD regardless its severity. The multivariate survival analysis in PAH-SSc patients confirmed age at diagnosis, worse NYHA-FC, increased PVR, reduced DLCO, and lower management with up-front combination therapy as major risk factors. In conclusion, in PAH-SSc cohort risk of death was greatly increased by clinical, PFT, and hemodynamic factors, whereas it was decreased by up-front combination therapy. Concomitant ILD worsened hemodynamics and PFT in PAH-SSc but not survival regardless of FVC impairment